返回
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.（2315.HK）價格
2315.HK 股價走勢圖
BIOCYTOGEN-B (2315.HK)
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
HK$39.72
-8.22%
$-3.56
休市： Jan 19, 16:00:00 HKT
暫無資料Earnings FAQ
2315.HK 最近的每股盈餘與預期相比如何？
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. 2315.HK 上一季度的收入表現如何？
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. 的收入預期是多少？
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. 的盈利品質評分是多少？
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. 何時發布財報？
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. 的預期收益是多少？
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. 是否超出收益預期？
關鍵數據
前收市價
$43.28
開盤價
$43.28
當日範圍
$39 - $43.28
52週區間
$7.25 - $48.26
交易量
2.3M
平均成交量
1.0M
每股盈餘 (TTM)
0.37
股息收益率
--
市值
$4.2B
什麼是 BIOCYTOGEN-B？
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. manufactures biological products and provides related biological services. The company is headquartered in Beijing, Beijing and currently employs 1,306 full-time employees. The company went IPO on 2022-09-01. The firm utilizes its self-developed RenMice fully human antibody and T-cell receptor (TCR) mouse platform for large-scale drug discovery and development targeting potential drug targets in the human body. The Company’s main businesses include the sale of innovative animal models, pre-clinical pharmacology and efficacy evaluation services, and antibody development. The firm is also engaged in the provision of gene-editing services. The firm operates its businesses in the domestic market and overseas markets.